APA (7th ed.) Citation

Rui Meng, Yingdan Cao, Ting Zhou, Hongfei Hu, & Yijin Qiu. (2022). The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Rui Meng, Yingdan Cao, Ting Zhou, Hongfei Hu, and Yijin Qiu. The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China. Frontiers Media S.A., 2022.

MLA (9th ed.) Citation

Rui Meng, et al. The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China. Frontiers Media S.A., 2022.